Overview

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Status:
Completed
Trial end date:
2006-05-19
Target enrollment:
Participant gender:
Summary
To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
SmithKline Beecham
Treatments:
Cyclophosphamide
Melphalan
Topotecan